Healthcare provider profile · identity verified

Laura Brudecki, DO

Allopathic & Osteopathic Physicians|Family Medicine · BLAINE, TN · NPI 1912437153

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Laura Brudecki, DO received $45.00 in general payments during 2025 across 1 reported records.

Lilly USA, LLC accounted for 100.0% of that reported general-payment amount.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Jardiance by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.

Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$45.00

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Lilly USA, LLC	Unresolved — no canonical attribution shown	$45.00	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Education	$45.00	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Payment records were found, but the reported records did not identify a specific associated product for this analysis.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557	Jardiance · 2024 Exact normalized brand match · 1 Part D row	90	24
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	MOUNJARO open payments reported associated product	CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455	Mounjaro · 2024 Exact normalized brand match · 1 Part D row	13	suppressed by CMS
Lilly USA, LLC Exact reporting entity; no affiliate inference	2025	TRULICITY open payments reported associated product	CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601	Trulicity · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	485	130
Atorvastatin Calcium	Atorvastatin Calcium	438	140
Gabapentin	Gabapentin	325	48
Levothyroxine Sodium	Levothyroxine Sodium	323	85
Omeprazole	Omeprazole	311	97
Albuterol Sulfate Hfa	Albuterol Sulfate	301	93
Amlodipine Besylate	Amlodipine Besylate	272	80
Losartan Potassium	Losartan Potassium	223	69
Pravastatin Sodium	Pravastatin Sodium	194	57
Metformin Hcl	Metformin Hcl	191	60
Pantoprazole Sodium	Pantoprazole Sodium	182	58
Furosemide	Furosemide	177	59
Hydrochlorothiazide	Hydrochlorothiazide	169	59
Buspirone Hcl	Buspirone Hcl	164	35
Ozempic	Semaglutide	155	30
Rosuvastatin Calcium	Rosuvastatin Calcium	120	42
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	114	37
Montelukast Sodium	Montelukast Sodium	112	29
Glimepiride	Glimepiride	111	40
Tizanidine Hcl	Tizanidine Hcl	111	17
Tamsulosin Hcl	Tamsulosin Hcl	109	35
Carvedilol	Carvedilol	108	35
Trazodone Hcl	Trazodone Hcl	108	26
Baclofen	Baclofen	97	21
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	97	29
Fluticasone Propionate	Fluticasone Propionate	93	34
Metoprolol Succinate	Metoprolol Succinate	92	27
Sertraline Hcl	Sertraline Hcl	92	31
Jardiance	Empagliflozin	90	24
Metformin Hcl Er	Metformin Hcl	88	31
Prednisone	Prednisone	88	71
Duloxetine Hcl	Duloxetine Hcl	87	22
Potassium Chloride	Potassium Chloride	87	24
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	76	20
Clopidogrel	Clopidogrel Bisulfate	74	22
Eliquis	Apixaban	73	21
Diclofenac Sodium	Diclofenac Sodium	70	31
Oxycodone Hcl	Oxycodone Hcl	70	suppressed
Allopurinol	Allopurinol	69	15
Promethazine Hcl	Promethazine Hcl	63	26
Fluoxetine Hcl	Fluoxetine Hcl	61	18
Metoprolol Tartrate	Metoprolol Tartrate	61	17
Atenolol	Atenolol	60	19
Famotidine	Famotidine	59	20
Farxiga	Dapagliflozin Propanediol	59	13
Pregabalin	Pregabalin	56	13
Meloxicam	Meloxicam	55	22
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	53	suppressed
Nystatin	Nystatin	52	20
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	15
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	49	16
Alendronate Sodium	Alendronate Sodium	48	17
Symbicort	Budesonide/Formoterol Fumarate	48	14
Ibuprofen	Ibuprofen	47	15
Methocarbamol	Methocarbamol	47	12
Esomeprazole Magnesium	Esomeprazole Magnesium	46	11
Doxycycline Monohydrate	Doxycycline Monohydrate	45	33
Ondansetron Hcl	Ondansetron Hcl	43	15
Quetiapine Fumarate	Quetiapine Fumarate	43	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	43	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	42	11
Nifedipine Er	Nifedipine	42	13
Hydralazine Hcl	Hydralazine Hcl	41	suppressed
Clonidine Hcl	Clonidine Hcl	40	suppressed
Paroxetine Hcl	Paroxetine Hcl	39	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	38	suppressed
Simvastatin	Simvastatin	38	14
Januvia	Sitagliptin Phosphate	37	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	35	18
Chlorthalidone	Chlorthalidone	34	12
Nurtec Odt	Rimegepant Sulfate	34	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	34	suppressed
Ezetimibe	Ezetimibe	33	suppressed
Lovastatin	Lovastatin	32	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	32	suppressed
Synthroid	Levothyroxine Sodium	32	suppressed
Ondansetron Odt	Ondansetron	31	12
Spironolactone	Spironolactone	31	suppressed
Telmisartan	Telmisartan	31	suppressed
Trulicity	Dulaglutide	31	suppressed
Bumetanide	Bumetanide	30	11
Levetiracetam	Levetiracetam	29	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	28	26
Humalog Kwikpen U-100	Insulin Lispro	28	12
Linzess	Linaclotide	28	suppressed
Mirtazapine	Mirtazapine	28	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	28	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	27	suppressed
Lidocaine	Lidocaine	27	suppressed
Bupropion Xl	Bupropion Hcl	26	suppressed
Topiramate	Topiramate	26	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Mupirocin	Mupirocin	25	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	25	suppressed
Alprazolam	Alprazolam	24	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	24	suppressed
Doxepin Hcl	Doxepin Hcl	24	suppressed
Ketoconazole	Ketoconazole	24	suppressed
Sucralfate	Sucralfate	24	15
Clonazepam	Clonazepam	23	suppressed
Fluconazole	Fluconazole	23	13
Clobetasol Propionate	Clobetasol Propionate	22	12
Estradiol	Estradiol	22	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	22	suppressed
Tramadol Hcl	Tramadol Hcl	22	suppressed
Ventolin Hfa	Albuterol Sulfate	22	suppressed
Azithromycin	Azithromycin	21	18
Ciprofloxacin Hcl	Ciprofloxacin Hcl	21	20
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Prazosin Hcl	Prazosin Hcl	21	suppressed
Primidone	Primidone	21	suppressed
Testosterone Cypionate	Testosterone Cypionate	21	suppressed
Warfarin Sodium	Warfarin Sodium	21	suppressed
Ropinirole Hcl	Ropinirole Hcl	20	suppressed
Aripiprazole	Aripiprazole	19	suppressed
Cefdinir	Cefdinir	19	18
Celecoxib	Celecoxib	19	suppressed
Glipizide Er	Glipizide	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Xarelto	Rivaroxaban	19	suppressed
Xtampza Er	Oxycodone Myristate	19	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	18	suppressed
Naproxen	Naproxen	18	suppressed
Spiriva Respimat	Tiotropium Bromide	18	suppressed
Cephalexin	Cephalexin	17	16
Droplet Pen Needle	Pen Needle, Diabetic	17	suppressed
Gemfibrozil	Gemfibrozil	17	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	17	16
Novolog Flexpen	Insulin Aspart	17	suppressed
Oxcarbazepine	Oxcarbazepine	17	suppressed
Tresiba Flextouch U-200	Insulin Degludec	17	suppressed
Amoxicillin	Amoxicillin	16	14
Colesevelam Hcl	Colesevelam Hcl	16	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	16	suppressed
Diazepam	Diazepam	15	suppressed
Valacyclovir	Valacyclovir Hcl	15	suppressed
Alcohol Prep Pads	Alcohol Antiseptic Pads	14	suppressed
Buprenorphine Hcl	Buprenorphine Hcl	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Rizatriptan	Rizatriptan Benzoate	14	suppressed
Spiriva Handihaler	Tiotropium Bromide	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	14	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	14	suppressed
Azelastine-Fluticasone	Azelastine/Fluticasone	13	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	13	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	13	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Torsemide	Torsemide	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Fluticasone Propionate Hfa	Fluticasone Propionate	12	suppressed
Glipizide	Glipizide	12	suppressed
Brilinta	Ticagrelor	11	suppressed
Glyburide	Glyburide	11	suppressed
Indapamide	Indapamide	11	suppressed
Meclizine Hcl	Meclizine Hcl	11	suppressed
Nabumetone	Nabumetone	11	suppressed
Serevent Diskus	Salmeterol Xinafoate	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$45.00 · 1 records	Lilly USA, LLC	—	3	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error